Psychedelic Medicine News Stories

Excerpts of Key Psychedelic Medicine News Stories in Major Media

Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Daniel Carcillo wanted two things in life: to play hockey and to be a father. By 30, he was a two-time Stanley Cup winner. By age 31, he was suicidal. After seven diagnosed concussions, Carcillo tells CNN that he was suffering from "dementia-like" symptoms, along with depression, anxiety and headaches. Carcillo says he also suffered from insomnia and disrupted sleep. He spent over $500,000 on prescription medications and treatments at stroke rehabilitation centers, brain centers, and concussion centers, as well as holistic therapies. Then in a "last-ditch effort" to try and alleviate his symptoms, he says he took a dose of psilocybin – the main psychoactive ingredient in magic mushrooms – in Denver, which became the first US city to decriminalize hallucinogenic mushrooms. "And I woke up the next day and I describe it as feeling the way I should," said Carcillo. "I felt like, for the first time in a very, very long time, I had a zest for life. All I wanted to do was get on FaceTime and call my wife and call my kids and get back home." Carcillo isn't the only athlete – former or current – openly talking about using psychedelics to treat various conditions. In 2022, residents in Colorado joined Oregon in voting to legalize psilocybin. Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder.

Note: Read more about the the healing potential of psychedelic medicine. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.

The psychedelic drug MDMA, also known as ecstasy or molly, has passed another key hurdle on its way to regulatory approval as a treatment for mental illness. A second large clinical trial has found that the drug – in combination with psychotherapy – is effective at treating post-traumatic stress disorder (PTSD). In June, Australia became the first country to allow physicians to prescribe MDMA for treating psychiatric conditions. MDMA is illegal in the United States and other countries because of the potential for its misuse. But the Multidisciplinary Association for Psychedelic Studies (MAPS) ... has long been developing a proprietary protocol for using MDMA as a treatment for PTSD and other disorders. MAPS has been campaigning for its legalization. In 2021, researchers sponsored by MAPS reported the results of a study in which 90 people received a form of psychotherapy developed by the organization alongside either MDMA or a placebo. After three treatment sessions, 67% of those who received MDMA with therapy no longer qualified for a PTSD diagnosis, compared with 32% of those who received therapy and a placebo. The results of a second trial ... were similar: 71% of people who received MDMA alongside therapy lost their PTSD diagnosis. A MAPS spokesperson says that the organization plans to seek formal FDA approval before the end of this year, and that because the agency has already designated MDMA as a ‘breakthrough therapy' ... it will be evaluated quickly.

Note: Read more about the healing potentials of mind-altering drugs. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.

Stuck indoors during the peak of COVID lockdown, science journalist Rachel Nuwer found herself at a professional crossroads. She had already published a nonfiction book on the dark world of wildlife trafficking and was looking for her next subject. A moment of clarity came at a surprising time. She and her partner, at home with nothing much to do, ingested MDMA. MDMA, also known as ecstasy or molly, is illegal. It is listed as a Schedule 1 drug by the U.S. federal government (the same group as marijuana and psilocybin, or magic mushrooms). A growing body of academic research has suggested potential benefits of MDMA beyond the recreational ecstasy some partygoers are familiar with. One study found that MDMA-enhanced therapy dramatically reduced PTSD symptoms. Another showed that psychedelics like MDMA could reopen so-called critical periods of time when brains are especially impressionable and open to learning. A scientific case study profiled a former white supremacist who reformed his extremist views after taking MDMA. Nuwer experienced similar clarity while on the drug. Her new book, "I Feel Love: MDMA and the Quest for Connection in a Fractured World," is the result of her epiphany. She explores the history and potential of the so-called love drug.

Note: Read more about the healing potentials of mind-altering drugs. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.

As of 2018, nearly one in eight Americans use antidepressants. Unfortunately, more than a third of patients are resistant to the mood-improving benefits of medicine's best antidepressant drugs. These people are not completely out of options. There are chemicals already out there that can restore their mood balance, and in some cases, even save their lives. Chemicals such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms) and dimethyltryptamine (DMT) are more accurately called "serotonergic psychedelics" among the neuroscience community. At the correct doses, psychedelics are well tolerated, producing only minor side effects such as transient fear, perception of illusions, nausea/vomiting or headaches. These fleeting side effects pale in comparison to the severity of commonly prescribed antidepressants, which include dangerous changes in heart rate and blood pressure, paradoxical increases in suicidality, and withdrawal symptoms. As far as outcomes go, psychedelics in combination with psychotherapy are remarkably efficient at treating depression. Compared to selective serotonin reuptake inhibitors, or SSRIs, the current gold standard in antidepressant medication, psychedelics have a faster effect on patients, sometimes effective with only a single therapy session. Psychedelics also have a longer-lasting effect than an SSRI regimen. A 2015 study ... demonstrated that past history of psychedelic use decreases the odds of suicidal thoughts or actions over the course of a lifetime.

Note: Read more about the healing potentials of psychedelic medicine. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.

Harriet de Wit, a professor of psychiatry and behavioural science at the University of Chicago, was running an experiment on whether the drug MDMA increased the pleasantness of social touch in healthy volunteers. Mike Bremmer, de Wit's research assistant, appeared at her office door with a concerned look on his face. A man named Brendan had filled out a standard questionnaire at the end. Strangely, at the very bottom of the form, Brendan had written in bold letters: "This experience has helped me sort out a debilitating personal issue. Google my name. I now know what I need to do." Brendan had been the leader of ... a notorious white nationalist group. "Go ask him what he means by 'I now know what I need to do,'" [de Wit] instructed Bremmer. As he clarified to Bremmer, love is what he had just realised he had to do. "Love is the most important thing," he told the baffled research assistant. "I conceived of my relationships with other people not as distinct boundaries with distinct entities, but more as we-are-all-one. I realised I'd been fixated on stuff that doesn't really matter. There are moments when I have racist or antisemitic thoughts ... But now I can recognise that those kinds of thought patterns are harming me more than anyone else." While MDMA cannot fix societal-level drivers of prejudice and disconnection, on an individual basis it can make a difference. In certain cases, the drug may even be able to help people see through the fog of discrimination and fear that divides so many of us.

Note: A case study about Brendan was published in the journal Biological Psychiatry. Read more on the healing potentials of psychedelic medicine, including science journalist Rachel Nuwer's new book, I Feel Love: MDMA and the Quest for Connection in a Fractured World. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

The World Health Organization estimates that ... depression and anxiety rose by more than 25 percent in the first year of the COVID pandemic, adding to the nearly one billion people who were already living with a mental disorder. One of the principal ways mental health disorders are thought to manifest is through severed connections between neurons – the winding, spindly cells in our brain and throughout our body essential for interpreting info from the external environment. Certain antidepressant drugs seem to work by increasing serotonin levels, an important neurotransmitter that the brain uses to send signals between neurons. They can help regrow neuronal connections ... only the effect seems to be slower, less dramatic [and] can come with significant drawbacks. In contrast, psychedelics can promote this kind of regrowth in as little as 24 hours, often less. Many experts believe psychedelic drugs ... act like Miracle Grow for neurons, helping them flourish like a dense forest. Pretty much the only reason drugs have a psychoactive effect on us at all is because they closely resemble chemicals our body already produces. Most psychedelic drugs like LSD, DMT and psilocybin are structurally similar to serotonin, so they can act on serotonin receptors, but in a slightly different way. You can think of it like clumsily-made lockpicks that still work in a lock designed for a specific key. But even the slight differences can have profound effects, specifically, altered perception of time and space and intensified colors and sounds.

Note: Read more on the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

The brew is so potent that practitioners report not only powerful hallucinations, but near-death experiences, contact with higher-dimensional beings, and life-transforming voyages through alternative realities. Often before throwing up, or having trouble at the other end. Now, scientists have gleaned deep insights of their own by monitoring the brain on DMT, or dimethyltryptamine, the psychedelic compound found in Psychotria viridis, the flowering shrub that is mashed up and boiled in the Amazonian drink, ayahuasca. The recordings reveal a profound impact across the brain, particularly in areas that are highly evolved in humans and instrumental in planning, language, memory, complex decision-making and imagination. The regions from which we conjure reality become hyperconnected, with communication more chaotic, fluid and flexible. "It is incredibly potent," said Robin Carhart-Harris, a professor of neurology and psychiatry. "People describe leaving this world and breaking through into another that is incredibly immersive and richly complex, sometimes being populated by other beings that they feel might hold special power over them, like gods." He added: "DMT breaks down the basic networks of the brain, causing them to become less distinct from each other. The major rhythms of the brain – that serve a largely inhibitory, constraining function – break down, and in concert, brain activity becomes more entropic or information-rich."

Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Australia has become the first country to recognise psychedelics as medicines, after the Therapeutic Goods Administration took researchers by surprise and approved the psychedelic substances in magic mushrooms and MDMA for use by people with certain mental health conditions. MDMA and psilocybin, the active ingredient in magic mushrooms, will be considered schedule 8 drugs - meaning they're approved for controlled use when prescribed by a psychiatrist - from July this year after the TGA acknowledged there were few other options for patients with specific treatment-resistant mental illnesses. The changes will allow MDMA to be used to treat post-traumatic stress disorder, and psilocybin for treatment-resistant depression. They will still be considered prohibited substances ... for all other usages. "Prescribing will be limited to psychiatrists, given their specialised qualifications and expertise to diagnose and treat patients with serious mental health conditions," a TGA statement published on Friday said. Associate Professor David Caldicott, an emergency department doctor who appeared at the Royal Commission into Defence and Veteran Suicide ... was pleasantly surprised by Friday's decision. "The conditions for which these drugs might be used [post-traumatic stress disorder and treatment-resistant depression] are currently conditions for which you're basically destined to a lifetime of drug use. Whereas the MDMA particularly is used to facilitate psychotherapy, only for a few doses," [said Caldicott].

Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Against all odds, Jim Harris was walking. There he was, at a music festival, getting around with the assistance of a walker, eight months out from a spinal-cord injury that left him paralyzed from the chest down. In November 2014, a snowkiting accident in Chile changed how the mountaineering instructor turned adventure photographer moved through the world. His days ... were now filled with rehabilitation exercises. A friend and former physical therapist invited him to the High Sierra Music Festival. "The disability made me feel like an outsider," he says. Then someone offered him magic mushrooms, which are packed with the psychoactive compound psilocybin. He commandeered an acquaintance's padded knee scooter so he could rest one leg at a time and still sway to the music. In the middle of a switch, he discovered that he could pick up his right foot and pull it back toward his butt. He tapped his right hamstring with a finger and the muscle contracted - a muscle that had been completely unresponsive since his injury, even in the low-gravity environment of a pool, despite eight months of physical therapy. With wonder and some degree of hesitation, he showed his physical-therapist friend. They marveled together at what had been impossible for Harris earlier that day. The next morning, Harris woke up afraid he'd imagined the whole thing, or that he'd lost his newfound ability while he slept, but his hamstring was still firing. The neuromuscular connection that had formed the night before wasn't going anywhere.

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Colorado is poised to become the second U.S. state to legalize medicinal psychedelics. Proposition 122, Access to Natural Psychedelic Substances, was supported by about 52% of the vote ... according to the Secretary of State's Office. The measure legalizes psilocybin and psilocin, two compounds found in "magic mushrooms," for use in therapeutic settings and paves the way for the establishment of "healing centers" where adults 21 years old and up can use the substances under the supervision of licensed professionals. Additionally, Proposition 122 decriminalizes the personal growing, use and sharing of psilocybin and psilocin, as well as ibogaine, mescaline and dimethyltryptamine, or DMT, for adults. Colorado follows Oregon, which legalized psilocybin in 2020. Natural Medicine Colorado lauded the results as a history-making win. "Colorado voters saw the benefit of regulated access to natural medicines, including psilocybin, so people with PTSD, terminal illness, depression, anxiety and other mental health issues can heal," said the measure's co-proponents, Kevin Matthews and Veronica Lightening Horse Perez, in a statement. Proposition 122 gives the Department of Regulatory Agencies (DORA) until January 2024 to develop licensing criteria for psychedelic treatment centers, facilitators, and ancillary businesses.

Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Key Articles From Years Past

Psychedelic therapy is the use of psychedelic substances, often alongside traditional talk therapy (psychotherapy), as a treatment for mental health issues such as anxiety, depression, suicidality and PTSD. Michael Mithoefer, M.D. ... at the Multidisciplinary Association for Psychedelic Studies (MAPS), likens psychedelic therapy to applying a cast to a broken bone. "[Psychedelic]-assisted therapy engages the mind's innate power to heal itself–the participants' ‘inner healing intelligence,'" claims Dr. Mithoefer, going on to explain that "the source of the healing process is the person themselves–the psychedelic and therapists are catalysts." In the U.S., psychedelics continue to undergo medical trials, with some being granted a "breakthrough therapy" designation by the FDA, indicating that preliminary clinical evidence has shown the drug can demonstrate substantial improvement over currently available therapy. COMPASS Pathways, a mental health treatment company, received the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute ... received the designation to continue its testing of psilocybin as a treatment for major depressive disorder. Psilocybin-assisted therapy is also being tested as a treatment for various addictions ... as well as certain conditions such as anxiety, depression, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), cluster headaches, migraines and chronic pain.

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Aaron Rodgers and Kenny Stills are among the few who have spoken publicly about their use of psychedelics for mental health purposes. But a future where the treatment is more widespread across sports may not be so far away. "Some people still ... don't recognize these as legitimate, life-saving medical medicines," [NBA agent Daniel] Poneman says. "There are athletes that I know who have had life-changing experiences with these medicines, but only a few of them are brave enough to speak out for fear of being stigmatized." There's still stigma around taking medication of any kind for mental illness, but it's slowly lessening. Aaron Rodgers said on a recent podcast that he has taken psychedelics to improve his mental health. The Packers' quarterback said he does not identify as having a mental illness like depression or anxiety, but that his most recent psychedelic experience–with ayahuasca, in March 2020, in Peru–has helped increase his "self-love." Before Rodgers spoke out, NFL free-agent wide receiver Kenny Stills was thought to be the only active professional athlete vocal about his psychedelic use. Stills, who last season played for the Saints, says his case of depression in 2016 felt like a "permanent cloud." Last year he went to a clinic run by Field Trip Health, a for-profit that provides people with ketamine-assisted psychotherapy–meaning they have to take the medication under supervision of a licensed therapist and debrief with them afterward.

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

A few weeks ago, I mentioned to a friend that I was interested in learning more about psychedelics, especially how they might help me with depression and anxiety. That's a broad category of plant medicines including psilocybin ("magic") mushrooms, MDMA (ecstasy), DMT (Dimitri or the Businessman's Trip), ketamine ("special K") and some others. My friend told me he'd recently taken his first "trip," which he described as life-changing. I asked him – a real estate developer living in Northern California, married with kids – why he decided to try a psychedelic substance. "My work felt increasingly stale and meaningless," he explained to me over a beer. "Despite a massive amount of reflection and coaching around how to break the rut, I felt as though I was still off track." When I confided my interest in psychedelics to a few other friends, several said they had tried the drugs and experienced several benefits: from easing anxiety to finding spiritual insights to combating depression and, among some with cancer, helping to reduce the fear of dying. They are hardly outliers. According to a new YouGovAmerica study, "one in four Americans say they've tried at least one psychedelic drug," amounting to some 72 million U.S. adults. When I queried my psychiatrist about participating to help improve my mental health, he was supportive, with two caveats: Do it with a trained therapist or guide, and do your best to ensure that the substance is what it's said to be.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

Growing evidence for the safety and efficacy of psychedelics could lead to better treatments for anxiety, depression, pain, and other often intractable conditions. Jerry Rosenbaum was intrigued when he first heard about the effect that psilocybin–the hallucinogenic compound found in certain species of mushrooms–was purported to have on the brain's "resting state," what neuroscientists call the default mode network. The default mode network encompasses any neural function that has some bearing on our autobiographical tendencies. When people take psilocybin at low doses, the default mode network becomes less active. That is, the drug appears to tame self-reflection and all but ruin rumination, that obsessive mental state characterized by excessive, repetitive thoughts. Rumination is a hallmark cognitive symptom of depression. Neuroscientists are observing that, when taken in a controlled setting, these substances are beneficial to the brain, especially for people who have certain psychiatric disorders. Landmark studies in 2014 and 2016 showed that LSD and psilocybin alleviated existential anxiety in patients with life-threatening illnesses for up to a year after beginning the treatment. Other studies have shown that ketamine may strengthen neurons against the damage from chronic stress by preventing synapses from being flooded with glutamate, an amino acid that, in excess, withers dendrites. And researchers continue to investigate whether psychedelics are useful as anti-inflammatory agents.

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that Cartography of the Mind: A Curated NFT Sale raised $1,569,960. Proceeds of the auction, presented by Christies in collaboration with Ryan Zurrer, founder of Dialectic and Vine Ventures, will benefit MAPS. Throughout the week, the physical exhibition at Christie's new gallery on 6th Avenue drew impressive crowds of enthusiastic visitors. With competitive bidding, the sale realized over $1.5 million. It was 100% sold, and 130% sold hammer over low estimate. Beeple, David Choe, Sarah Meyohas, Refik Anadol, Mad Dog Jones, IX Shells, and more donated art to support MAPS. The research, education, and advocacy organization ... remains the leading body at the vanguard of research into potentially life-saving psychedelic-assisted therapies. Psychedelic Healing is an artistic interpretation of the MAPS logo by renowned artist Alex Grey to celebrate MAPS' 35th anniversary in 2021. It was purchased by Ryan Zurrer and donated back to MAPS for additional fundraising. Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world funded primarily by philanthropic donors and grantors who have given more than $130 million for research and education.

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

As twin mental health and drug misuse crises kill thousands of people per week, the potential of psychedelic-assisted therapies "must be explored," urges a federal letter on behalf of the U.S. health secretary. President Joe Biden's administration "anticipates" that regulators will approve MDMA and psilocybin within the next two years for designated breakthrough therapies for PTSD and depression, respectively. The administration is "exploring the prospect of establishing a federal task force to monitor" the emerging psychedelic treatment ecosystem, according to the letter sent by Assistant Secretary for Mental Health and Substance Use. The move followed [the] introduction of a bipartisan bill, co-sponsored by Sens. Cory Booker, D-N.J., and Rand Paul, R-Ky., to force the DEA to stop barring terminally ill patients from trying controlled drugs which have passed early trials. The right to try experimental therapies has been enshrined in federal law since 2018, but the DEA currently blocks its use among people with late-stage cancer who wish to be treated with psilocybin, a Schedule I controlled substance. "Studies have shown that psilocybin produces substantial and sustained decreases in depression and anxiety among patients with life-threatening cancer," Booker wrote. "While typically terminally ill patients are allowed to access drugs that are in FDA clinical trials, they are barred from accessing Schedule I drugs, despite their therapeutic potential."

Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Jose Martinez, a former Army gunner whose right arm and both legs were blown off by a roadside bomb in Afghanistan, has a new calling: He's become one of the most effective lobbyists in a campaign to legalize the therapeutic use of psychedelic drugs across the country. On a Zoom call ... with Connie Leyva, a Democratic legislator in California who has long opposed relaxing drug laws, Mr. Martinez told her how psilocybin, the psychoactive ingredient in "magic" mushrooms, had helped to finally quell the physical pain and suicidal thoughts that had tormented him. Ms. Leyva says she changed her mind even before the call ended, and she later voted yes on the bill, which is expected to become law early next year. In the two years since Oregon, Washington, D.C., and a half-dozen municipalities decriminalized psilocybin, vets have become leading advocates in the drive to legalize psychedelic medicine, which they credit with helping ease the post-traumatic stress, anxiety and depression that are often tied to their experiences in the military. The campaign has been propelled by the epidemic of suicides among veterans ... but also by the national reckoning over the mass incarceration of people on drug charges. More than 30,000 service members have taken their own lives in the years since Sept. 11 – four times the number of those who died on the battlefield. "I will not be told no on something that prevents human beings from killing themselves," Mr. Martinez said.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

Mr. McCourry, a former U.S. Marine, had been crippled by post-traumatic stress disorder ever since returning from Iraq in 2004. He could not sleep, pushed away friends and family and developed a drinking problem. The numbness he felt was broken only by bouts of rage and paranoia. He was contemplating suicide when his sister heard about a novel clinical trial using the psychedelic drug MDMA, paired with therapy, to treat PTSD. Desperate, he enrolled in 2012. PTSD is a major public health problem worldwide and is particularly associated with war. In the United States, an estimated 13 percent of combat veterans and up to 20 to 25 percent of those deployed to Iraq and Afghanistan are diagnosed with PTSD at some point in their lives, compared with seven percent of the general population. There is growing evidence that MDMA – the illegal drug known as Ecstasy or Molly – can significantly lessen or even eliminate symptoms of PTSD when the treatment is paired with talk therapy. Last year, scientists reported in Nature Medicine the most encouraging results to date. The 90 participants in the study had all suffered from severe PTSD for more than 14 years on average. Each received three therapy sessions with either MDMA or a placebo, spaced one month apart and overseen by a two-person therapist team. Two months after treatment, 67 percent of those who received MDMA no longer qualified for a PTSD diagnosis, compared with 32 percent who received the placebo. As in previous trials, MDMA caused no serious side effects.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.

Massachusetts General Hospital wouldn't seem like a natural fit for a center devoted to mind-altering drugs. But this week, MGH launched the Center for the Neuroscience of Psychedelics to study the potential of psilocybin and other psychoactive drugs to treat conditions such as depression, addiction, trauma, and more. The new center at MGH signifies that the field of psychedelic therapy has arrived. Inspiration came from the search for ways to ease the misery of patients whose mental illness is resistant to traditional treatments. Psychedelics are known to facilitate "plasticity" in the brain, increasing its capacity for change, and [director Jerrold] Rosenbaum said his team wanted to understand how these agents "move the brain to change in a way that can address many of the most anguishing forms of human suffering." The MGH center combines the disciplines of psychiatry, brain imaging, genomic medicine, and chemical biology. Some of the initial work involving patients will use psilocybin and be directed at rumination – the stuck, repetitive thought patterns that underlie several conditions, from addiction to obsessive-compulsive disorder. The future of the center's research is boundless, since psychedelics' role in neuroplasticity and neuritogenesis – the ability to build new synapses – may be useful in palliative care with terminally ill patients as well as in combatting neurodegenerative diseases such as Parkinson's and Alzheimer's.

Note: This article is also available on this webpage. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.

Evan, a middle-class Black man, doesn't come across as a psychedelic enthusiast. He's a 23-year-old quantitative economics graduate student who takes pride in steaming his sweater vests to maintain a studious appearance. In 2015, Evan's father was arrested for misdemeanor drug possession. A teenager at the time, he swore off drugs forever. But six years later, magic mushrooms have become Evan's remedy to cope with racial trauma. Like most Americans, Evan followed the widespread media coverage of George Floyd and Breonna Taylor's deaths in 2020. And like many Black Americans, he experienced traumatic-stress symptoms triggered by the constant exposure to cases of police brutality and racial discrimination. Debilitating panic attacks incapacitated him multiple times a day; insomnia drained his ... energy. After unsuccessfully trying three different anti-anxiety medications, he finally stumbled upon a study on psychedelics for racial trauma. He wondered: could psychedelic therapy be the solution? Psilocybin, the active compound in magic mushrooms, has been found to mitigate acute anxiety among patients with life-threatening cancer. A state-sponsored study in Texas is investigating psychedelics as a treatment for post-traumatic stress disorder in veterans. But one lesser-known benefit has been documented by researchers at the University of Ottawa: psychedelics may alleviate symptoms of race-based traumatic stress.

Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.